Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Metagenomi Therapeutics, Inc. MGX

Healthcare  —  Biotechnology
1.15 0.00 0.00% as of 25 Sep
Market cap
$43.4M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Metagenomi, Inc. (MGX) Business Profile

Updated before January 2025

Company Overview

Metagenomi, Inc. (MGX) is a biotechnology company specializing in the development of advanced gene-editing technologies. Founded in 2018 by Dr. Brian C. Thomas and Dr. Jillian F. Banfield, the company is headquartered in Emeryville, California. Metagenomi emerged from groundbreaking research in metagenomics, a field that studies genetic material recovered directly from environmental samples. The company leverages this expertise to discover novel enzymes and develop innovative solutions for gene editing and therapeutic applications.

The leadership team at Metagenomi includes experienced professionals from the biotechnology and pharmaceutical industries. Dr. Brian C. Thomas serves as the CEO, bringing years of expertise in metagenomics and synthetic biology. Dr. Jillian F. Banfield, a co-founder, is a renowned scientist in the field of microbiology and metagenomics. The company’s leadership is complemented by a team of experts in molecular biology, bioinformatics, and clinical development.

Core Business Segments

Metagenomi operates in the following core business segments:

Gene-Editing Platforms

Metagenomi’s primary focus is on developing next-generation gene-editing tools. The company has discovered a suite of novel CRISPR-associated enzymes that offer improved precision, efficiency, and versatility compared to traditional CRISPR systems. These tools are designed for a wide range of applications, including therapeutic gene editing, agricultural biotechnology, and industrial processes.

Therapeutic Development

Metagenomi collaborates with pharmaceutical companies to develop gene-editing therapies for genetic disorders, cancers, and other diseases. By leveraging its proprietary gene-editing platforms, the company aims to create safer and more effective treatments. Key therapeutic areas include:

  • Rare Genetic Disorders: Developing gene therapies to address unmet medical needs.
  • Oncology: Creating innovative treatments for various types of cancer.

Research and Development Services

Metagenomi offers R&D services to academic institutions, biotech companies, and pharmaceutical firms. These services include enzyme discovery, bioinformatics analysis, and custom gene-editing solutions tailored to specific research needs.

Business Model

Metagenomi’s business model is built on a combination of technology licensing, partnerships, and in-house therapeutic development. The company generates revenue through:

  • Licensing Agreements: Licensing its proprietary gene-editing technologies to biotech and pharmaceutical companies.
  • Collaborative Partnerships: Partnering with organizations to co-develop gene-editing therapies and share in the resulting revenues.
  • Service Contracts: Providing specialized R&D services to external clients.

This diversified approach allows Metagenomi to capitalize on its technological innovations while mitigating risks associated with drug development.

Strategic Direction

Metagenomi is focused on expanding its capabilities and market presence through the following strategies:

  • Pipeline Expansion: Developing a robust pipeline of gene-editing therapies targeting a wide range of diseases.
  • Global Partnerships: Establishing collaborations with leading pharmaceutical companies to accelerate the development and commercialization of its technologies.
  • Sustainability Goals: Incorporating sustainable practices in its operations, including the use of environmentally friendly materials and processes.
  • New Product Categories: Exploring applications of its gene-editing tools in agriculture and industrial biotechnology to diversify its revenue streams.

Competitive Landscape

Metagenomi operates in a highly competitive market, facing competition from established players and emerging startups. Key competitors include:

  • Editas Medicine: A pioneer in CRISPR-based gene editing.
  • Intellia Therapeutics: Focused on developing CRISPR therapies for genetic diseases.
  • CRISPR Therapeutics: Known for its work in gene-editing therapies for blood disorders and cancer.
  • Beam Therapeutics: Specializing in base editing, a next-generation gene-editing technology.

Despite the competition, Metagenomi differentiates itself through its proprietary enzyme discovery platform and focus on novel CRISPR-associated systems.

Risk Factors

Metagenomi faces several risks that could impact its business:

  • Regulatory Challenges: Navigating complex regulatory pathways for gene-editing therapies.
  • Market Dependence: Reliance on partnerships and licensing agreements for revenue generation.
  • Supply Chain Disruptions: Potential delays in obtaining raw materials and equipment for R&D and manufacturing.
  • Technological Risks: The possibility of competitors developing superior gene-editing technologies.

Recent Developments

Metagenomi has made significant strides in recent years, including:

  • New Enzyme Discoveries: Identifying novel CRISPR-associated enzymes with enhanced capabilities.
  • Partnerships: Collaborating with major pharmaceutical companies to advance gene-editing therapies.
  • Funding Rounds: Securing substantial investments to support R&D and commercialization efforts.
  • Global Trends: Adapting to the increasing demand for gene-editing solutions in healthcare and agriculture.

Investment Considerations

Strengths

  • Proprietary gene-editing technologies with broad applications.
  • Strong leadership team with expertise in metagenomics and biotechnology.
  • Diversified revenue streams through licensing, partnerships, and services.

Risks

  • High R&D costs and long development timelines for therapeutic products.
  • Dependence on external partnerships for commercialization.
  • Regulatory and ethical challenges associated with gene editing.

Conclusion

Metagenomi, Inc. is at the forefront of the gene-editing revolution, leveraging its expertise in metagenomics to develop innovative solutions for healthcare and beyond. With a strong pipeline, strategic partnerships, and a commitment to sustainability, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with this emerging field before making investment decisions.